Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and-2 Studies Compared to a Real-World Dataset

被引：0
|
作者：
Charlton, Michael R. [1 ]
Cheung, Michelle C. [2 ]
Manns, Michael P. [3 ,4 ]
Sajed, Nika [5 ]
Troke, Philip [6 ]
Spellman, James G. [5 ]
Copans, Amanda [5 ]
Arterburn, Sarah [5 ]
Brainard, Diana M. [5 ]
Irving, William [7 ]
Foster, Graham R. [2 ]
机构：
[1] Intermt Med Ctr, Div Hepatol & Liver Transplantat, Salt Lake City, UT USA
[2] Queen Mary Univ London, Blizard Inst, Liver Unit, London, England
[3] Hannover Med Sch, Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[4] German Ctr Infect Res DZIF, Hannover, Germany
[5] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[6] Gilead Sci Ltd, London, England
[7] NIHR Nottingham Digest Dis Biomed Res Unit, Nottingham, England
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
966
引用
收藏
页码：489A / 490A
页数：2
相关论文
共 50 条
  • [1] Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-world Dataset
    Charlton, M.
    Cheung, M. C. M.
    Manns, M.
    Sajed, N.
    Troke, P. J. F.
    Spellman, J.
    Copans, A.
    Arterburn, S.
    Brainard, D. M.
    Irving, W. L.
    Foster, G. R.
    [J]. TRANSPLANTATION, 2017, 101 (05) : 92 - 92
  • [2] LDV/SOF plus RBV in HCV Patients with Decompensated Cirrhosis or Liver Transplantation: Data from the SOLAR-1 and-2 Trials
    Curry, M. P.
    Gane, E.
    Manns, M.
    McCaughan, G.
    Peck-Radosavljevic, M.
    Van Vlierberghe, H.
    Denning, J.
    Brainard, D. M.
    McHutchison, J. G.
    Kumar, P.
    Yoshida, E.
    Colombo, M.
    Van Hoeck, B.
    Dufour, J.
    Landis, C.
    Brown, R.
    Mutimer, D.
    Flamm, S. L.
    Charlton, M.
    Reddy, K. R.
    Samuel, D.
    Everson, G. T.
    Forns, X.
    [J]. TRANSPLANTATION, 2016, 100 : S225 - S225
  • [3] Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1
    Buggisch, P.
    Moreno, A.
    Isakov, V.
    Backus, L.
    Ain, D.
    Ruane, P.
    Gonzalez, J.
    Naik, S.
    Mehta, S.
    Lee, J.
    Mertens, M.
    Natha, M.
    Kersey, K.
    Osinusi, A.
    Zhdanov, K.
    Berenguer, J.
    Zeuzem, S.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S729 - S730
  • [4] Use of Ledipasvir/Sofosbuvir (LDV/SOF) with or without Ribavirin (RBV) in Genotype 1 (GT 1) HCV-infected Patients Post Liver Transplant (LT): Evaluation of Several Real-world Datasets (RWD)
    Bourliere, Marc
    Charlton, Michael R.
    Manns, Michael P.
    Prieto, Martin
    Fernandez, Inmaculada
    Londono, Maria-Carlota
    Kwok, Ryan M.
    Smith, Coleman
    Lee, Stacey
    Zhang, Jie
    Arterburn, Sarah
    Osinusi, Anu O.
    Le, Hadley
    Copans, Amanda
    Rossaro, Lorenzo
    Curry, Michael P.
    Flamm, Steven L.
    [J]. HEPATOLOGY, 2016, 64 : 963A - 964A
  • [5] Treatment Response to 12 Weeks of Simeprevir plus Sofosbuvir±Ribavirin (SMV plus SOF±RBV): A Meta-Analysis of 7 Studies With 715 HCV Genotype 1 (HCV-1) Patients
    Yee, Brittany E.
    Nghia Nguyen
    Lutchman, Glen
    Lim, Joseph K.
    Nguyen, Mindie H.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1088 - S1089
  • [6] HIGH EFFICACY OF LEDIPASVIR/SOFOSBUVIR PLUS RIBAVIRIN AMONG PATIENTS WITH DECOMPENSATED CIRRHOSIS WHO UNDERWENT LIVER TRANSPLANT DURING PARTICIPATION IN THE SOLAR-1 AND-2 STUDIES
    Mullhaupt, B.
    Kwo, P.
    Agarwal, K.
    Duvoux, C.
    Durand, F.
    Peck-Radosavljevic, M.
    Yoshida, E. M.
    Lilly, L.
    Willems, B.
    Vargas, H.
    Kumar, P.
    Brown, R. S.
    Horsmans, Y.
    De-Oertel, S.
    Arterburn, S.
    Dvory-Sobol, H.
    Brainard, D. M.
    McHutchison, J. G.
    Terrault, N.
    Rizzetto, M.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S749 - S749
  • [7] Real-World Retreatment of Sofosbuvir/Ledipasvir (SOF/LDV) Failures In Hepatitis C Virus Genotype 1 infection
    Pearlman, Brian
    Hinds, Andrew
    Perrys, Michael
    [J]. HEPATOLOGY, 2016, 64 : 478A - 478A
  • [8] Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
    Sulkowski, Mark S.
    Vargas, Hugo E.
    Di Bisceglie, Adrian M.
    Kuo, Alexander
    Reddy, K. Rajender
    Lim, Joseph K.
    Morelli, Giuseppe
    Darling, Jama M.
    Feld, Jordan J.
    Brown, Robert S.
    Frazier, Lynn M.
    Stewart, Thomas G.
    Fried, Michael W.
    Nelson, David R.
    Jacobson, Ira M.
    [J]. GASTROENTEROLOGY, 2016, 150 (02) : 419 - 429
  • [9] Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection
    Pol, S.
    Aghemo, A.
    Lin, L.
    Hyland, R.
    Yun, C.
    Spellman, J.
    Natha, M.
    Brainard, D.
    McHutchison, J.
    Bourliere, M.
    Peck-Radosavljevic, M.
    Michael, M.
    Colombo, M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 262 - 262
  • [10] OUTCOMES OF 12-WEEK THERAPY WITH SIMEPREVIR plus SOFOSBUVIR plus /- RIBAVIRIN (SMV plus SOF±RBV): A META-ANALYSIS OF 7 STUDIES AND 715 HCV GENOTYPE 1 (HCV-1) PATIENTS
    Yee, B. E.
    Nguyen, N. H.
    Lutchman, G. A.
    Lim, J. K.
    Nguyen, M. H.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S668 - S669
12345